Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix | MicrobiomeTrials← Back to trialsNCT03305341
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2025-05-18Est. Completion: 2026-11-18
Enrollment target: 20 participants Locations- Medicine Invention Design Incorporation (MIDI) - IORG0007849, North Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Diet, Healthy
Restaurants are normative eating contexts for many families. Restaurant meals tend to be higher in calories and lower in…
Buffalo, United StatesCompleted Nov 22, 2024
SARS-CoV-2Influenza, HumanRespiratory Syncytial Virus InfectionsRespiratory Distress SyndromeSystemic Inflammatory Response Syndrome
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B)…
Alcalá de Henares, SpainEst. completion Oct 2, 2026